Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 420Lymphoma, Large B-Cell, Diffuse 93Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 79Recurrence 68Lymphoma 60Neoplasms, Plasma Cell 57Lymphoma, Mantle-Cell 56Lymphoma, B-Cell, Marginal Zone 47Lymphoma, Non-Hodgkin 46Leukemia, Myeloid, Acute 34Leukemia 32Lymphoma, B-Cell 24Neoplasms 23Myelodysplastic Syndromes 23Waldenstrom Macroglobulinemia 18Hodgkin Disease 18Smoldering Multiple Myeloma 17Lymphoma, T-Cell, Peripheral 16Burkitt Lymphoma 14Hematologic Diseases 13Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Prostatic Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Sezary Syndrome 10Mycosis Fungoides 10Lymphoma, Large-Cell, Anaplastic 9Leukemia, Myelomonocytic, Chronic 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

pomalidomide 1Lenalidomide 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Malignant Plasma Cell Neoplasms × Lenalidomide × Clear all
NCT07560449 2026-05-01

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

Qilu Pharmaceutical Co., Ltd.

Phase 2 Not yet recruiting
162 enrolled
Plasma cell

Malignant Plasma Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡